The specifics, since they change the answer: triglycerides · ten weeks · a GLP-1 receptor agonist.
Something has gone wrong and I would like to know how badly before I decide what to do.
Nothing else in the setup changed, which is what makes this puzzling.
What would you check first, and what would you conclude from each outcome?
10 weeks is 70 days, and the first question about any marker is whether 70 days is long enough for it to have finished moving. Triglycerides are the most volatile line on the panel: the fasting interval and the previous evening move them further than a month of treatment does. Against 70 days that puts the marker well inside its own settling time, so the value is reporting a new steady state rather than a transient. The second question is the denominator. Weight loss moves plasma volume, muscle mass and intake at once, and several of the markers on a routine panel are ratios with one of those three underneath them. Repeat before interpreting. A single value 70 days in, with no baseline drawn under the same conditions, is a number rather than a change — and nothing here is medical advice.
The short version: a small, well-chosen panel with a baseline beats a large one without.
A twenty-analyte panel run on a healthy person will produce, on average, one out-of-range result purely from how reference intervals are constructed. That is arithmetic rather than pathology.
| Quantity | Value | Derivation |
|---|---|---|
| Control-arm event rate | 8.0 % | From the trial table, not the abstract |
| Hazard ratio | 0.80 | Reported |
| Treated event rate | 6.4 % | 8.0 × 0.80 |
| Absolute risk reduction | 1.6 pp | 8.0 − 6.4 |
| Number needed to treat | 63 | 1 ÷ 0.016 |
| Relative risk reduction | 20 % | 1 − 0.80 |
The last two rows describe the same finding. Only one of them is used in headlines.
Repeat before you react. A single abnormal value has a substantial probability of being within the combined biological and analytical variation of a normal one.
Reference intervals are conventionally the central ninety-five per cent of a reference population, which is the direct cause of the one-in-twenty out-of-range rate on a healthy panel.
The caveat is that a panel is not a diagnosis and interpreting one is a clinician's job, particularly when several values move together.
Baseline first, then a repeat under identical conditions. Everything else is secondary.
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standardsThe honest position is that most people order too many analytes and too few time points, when the reverse would be more informative.
Delta checks — comparing against your own previous value — are far more sensitive than comparing against a population interval, which is the argument for keeping a series rather than a snapshot.
Keep the reports rather than the numbers. Units, reference intervals and methods all vary, and a bare number two years later is not comparable to anything.
Pre-analytical factors — posture, tourniquet time, fasting, sample handling — are the largest source of error in routine biochemistry, well ahead of the analysis itself.
Ordering tests you will not act on generates anxiety and incidental findings, both of which have costs.
Keep the full report, not the number. You will need the units and the interval later.
Answer first: decide what you would do differently for each possible result before you order the panel. Anything that fails that test is a number you will worry about and not act on.
Same laboratory, same method, same time of day, same fasting state. Between-laboratory differences on several common analytes are larger than the changes people are trying to detect.
Haemolysis in the sample raises potassium and several enzymes spuriously. If a result is bizarre, ask whether the sample was flagged before building a theory on it.
Nothing here is medical advice. If something is out of range and you do not know why, that is a consultation rather than a research project.
Same laboratory, same time, same fasting state, or the comparison is not a comparison.
To be exact about it, this is answerable, and the answer is mostly about which tests rather than how many.
A sensible core for this population is a full blood count, renal function with electrolytes, liver enzymes with bilirubin, a fasting lipid panel with apolipoprotein B, HbA1c and thyroid-stimulating hormone.
External quality assurance schemes document between-laboratory differences on common analytes that routinely exceed the size of clinically interesting changes.
Decide the action for each result before you order the test.
Before reacting to any single value, check whether it is outside the interval by an amount larger than the assay's own variation.
Timing matters per analyte: cortisol and testosterone are diurnal, triglycerides are postprandial, and creatinine responds to hydration and to recent training. Fixing the conditions removes most of the noise.
Biological variation data are published per analyte and are the basis for the reference change value — the difference between two results that is larger than noise.
One out-of-range value on a twenty-analyte panel is expected. Two on a repeat is a finding.
edited 29 Nov 2025 by lyoph_cake — updated for the 2026 guidance change
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.